Pancreatic Cancer Clinical Trials

Yes. Trials for early-stage (resectable) pancreatic cancer typically focus on neoadjuvant therapy given before surgery to shrink the tumor, or adjuvant therapy given after surgery to reduce the chance of recurrence. These trials are important because even after successful surgery, the recurrence rate remains high with standard treatment alone.

Standard single-agent immunotherapy has been largely ineffective for most pancreatic cancers, but researchers are testing combinations designed to overcome this resistance. Current trials are pairing checkpoint inhibitors with vaccines, radiation, stromal modifiers, and other agents. A small subset of patients with MSI-high tumors do respond to immunotherapy, which is why genetic testing matters.

While pancreatic cancer is often time-sensitive, most trials have a screening window of two to four weeks. It is worth taking a few days to understand the trial thoroughly before committing. Your oncologist can help you weigh the urgency of starting treatment against the potential benefits of a trial.

No. Clinical trial participation and palliative care are not mutually exclusive. Palliative care focuses on symptom management and quality of life and should continue alongside any cancer treatment. Many trials now integrate palliative care assessments as part of the study protocol.

Major cancer centers with pancreatic cancer expertise often have the broadest selection of trials, and traveling for treatment is common for this disease. Some trials offer travel stipends or can arrange for certain visits to occur with a local oncologist. Ask the trial team about remote monitoring options and financial assistance programs.